K100344

APR 18 2011

510(k) Summary of Safety and Effectiveness for the

LOCI CA 15-3 (CA 15-3) Flex® Reagent Cartridge

Dimension Vista® LOCI® Calibrator

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

A. 510(k) Number: k100344

B. Date of Preparation: January 27, 2010

C. Proprietary and Established Names:

LOCI CA 15-3 Flex® Reagent Cartridge

Dimension Vista® LOCI 7 Calibrator

D. Applicant:

Siemens Healthcare Diagnostics Inc.

P.O. Box 6101, Newark, DE 19714-6101

Pamela A. Jurga, Regulatory & Clinical Affairs Specialist

Office Number: (302) 631-8891 fax Number: (302) 631-6299

E. Regulatory Information:

LOCI CA15-3 Flex® Reagent Cartridge:

1. Regulation section: 21 CFR § 866.6010 Tumor-Associated antigen immunological test system
2. Classification: Class II
3. Product Code: MOI – System, Test, Immunological, Antigen, Tumor
4. Panel: Immunology

LOCI 7 Calibrator:

1. Regulation section: 21 CFR § 862.1150 Calibrator
2. Classification: Class II
3. Product Code: JIT – Calibrator, Secondary
4. Panel: Immunology

F. Predicate Device:

The predicate device used to demonstrate substantial equivalence to the LOCI CA 15-3 Flex® Reagent Cartridge is the CA 15-3 Assay for the ADVIA Centaur System previously cleared under K012357 .

The predicate device used to demonstrate substantial equivalence to the Dimension Vista® LOCI 7 Calibrator is the Calibrator for the Access® BR Monitor Assay previously cleared under K072612 .

G. Device Description:

The LOCI CA 15-3 (CA 15-3) method is a homogeneous, sandwich chemiluminescent immunoassay based on LOCI® technology. The LOCI® reagents include two synthetic bead reagents and a biotinylated anti-CA 15-3 monoclonal antibody (DF3) fragment. The first bead reagent (Chemibeads) is coated with an anti-CA15-3 monoclonal antibody (115D8) and contains a chemiluminescent dye. The second bead reagent (Sensibeads) is coated with streptavidin and contains a photosensitizer dye. Sample is incubated with biotinylated antibody and Chemibeads to form bead-CA 15-3-biotinylated antibody sandwiches. Sensibeads are added and bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the CA 15-3 concentration in the sample.

The LOCI 7 calibrator is a liquid, frozen, bovine serum albumin, based product containing CA 15-3 from human cell culture. The kit consists of ten vials, two vials per level (A-E), 2.0 mL per vial. Description of the manufacturing, value assignment and stability testing process are provided in this submission report.

H. Intended Use:

The LOCI CA 15-3 method is an *in vitro* diagnostic test for the quantitative measurement of CA 15-3 in human serum and lithium heparin and EDTA plasma on the Dimension Vista® System. When used in conjunction with other clinical and diagnostic procedures, serial testing with the LOCI CA 15-3 assay may be used as an aid in the management of previously treated stage II and III breast cancer patients and for monitoring response to therapy in metastatic breast cancer patients.

The LOCI 7 CAL is an *in vitro* diagnostic product for the calibration of Cancer Antigen 15-3 (CA 15-3) and Cancer Antigen 19-9 (CA 19-9) methods on the Dimension Vista® system.

I. Substantial Equivalence Information:

The LOCI CA 15-3 method is substantially equivalent to other CA15-3 test systems such as the ADVIA Centaur CA15-3 assay (k012357). The LOCI 7 calibrator is substantially equivalent to other calibrators such as the CA 15-3 calibrator for the CA 15-3 Assay for the ADVIA Centaur System (k012357). The following table provides a comparison of the important similarities and differences:

Feature	LOCI CA 15-3 Flex® reagent cartridge	CA 15-3® Assay for the ADVIA Centaur System (k012357)
Intended Use	The LOCI CA15-3 method is an *in vitro* diagnostic test for the quantitative measurement of CA 15-3 in human serum and lithium heparin and EDTA plasma on the Dimension Vista® System. When used in conjunction with other clinical and diagnostic procedures, serial testing with the LOCI CA 15-3 assay may be used as an aid in the management of previously treated stage II and III breast cancer patients and for monitoring response to therapy in metastatic breast cancer patients.	The ADVIA Centaur CA 15-3 assay is an *in vitro* diagnostic test for the quantitative serial determination of cancer antigen CA 15-3 in human serum using the ADVIA Centaur and the ADVIA Centaur XP systems. When used in conjunction with other clinical and diagnostic procedures, serial testing with the ADVIA Centaur CA 15-3 assay is useful for monitoring the course for disease and therapy in metastatic breast cancer patients, and for detection of recurrence in previously treated Stage II, with greater than two positive lymph nodes, or Stage III breast cancer patients. This assay is not intended for use on any other system.
Sample Type	Serum, lithium heparin and EDTA plasma	Serum
Measuring Range	1.0-300.0 U/mL	0.5-200 U/mL
Sample Size	1 µL	20 µL
Measurement	Chemiluminescent: Homogenous sandwich immunoassay based on LOCI® technology	Chemiluminescent: Two site sandwich immunoassay using direct chemiluminometric technology

Feature	LOCI 7 calibrator	Access BR Monitor (CA 15-3 Antigen) Assay on the Access Immunoassay Systems (k072612)
Intended Use	The LOCI 7 CAL is an *in vitro* diagnostic product for the calibration of Cancer Antigen 15-3 (CA 15-3) and Cancer Antigen 19-9 (CA 19-9) methods on the Dimension Vista® system.	For *in vitro* diagnostic use for the calibration the Access BR Monitor (CA 15-3 Antigen) Assay.
Matrix	Bovine Serum Albumin	Bovine Serum Albumin
Levels	5 levels at approximately 0, 20, 60, 150, 315 U/mL	6 levels at approximately 0, 10, 50, 100, 500 and 1000 U/mL
Preparation	Liquid	Lyophilized
Storage	Store at -25 to -15 °C.	Store at 2 to 8°C.

J. Conclusion:

The LOCI CA 15-3 method Flex® reagent cartridge is substantially equivalent to the ADVIA Centaur CA 15-3-3 Assay previously cleared under K012357. The LOCI 7 calibrator is substantially equivalent to the ACCESS BR Monitor (CA 15-3 Antigen) Calibrators previously cleared under k072612. Comparative testing described in the submission report demonstrates substantial equivalent performance.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Siemens Healthcare Diagnostics
c/o Ms. Pamela A. Jurga
Regulatory and Clinical Affairs Specialist
PO Box 6101
Mailstop 514
Newark, DE 19714-6101

APR 18 2011

Re: k100344
Trade/Device Name: Dimension Vista® LOCI CA 15-3 Flex® reagent cartridge
Dimension Vista® LOCI 7 Calibrator
Regulation Number: 21 CFR §866.6010
Regulation Name: Tumor-associated antigen immunological test system
Regulatory Class: Class II
Product Code: MOI, JIX
Dated: April 11, 2011
Received: April 12, 2011

Dear Ms. Jurga:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan

Maria M. Chan, Ph.D.
Director
Division of Immunology and Hematology Devices
Office of *In Vitro* Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): k100344

Device Name: Dimension Vista® LOCI CA 15-3 Flex® reagent cartridge

Indications for Use:

The LOCI CA15-3 method is an *in vitro* diagnostic test for the quantitative measurement of CA 15-3 in human serum and lithium heparin and EDTA plasma on the Dimension Vista® System. When used in conjunction with other clinical and diagnostic procedures, serial testing with the LOCI CA 15-3 assay may be used as an aid in the management of previously treated stage II and III breast cancer patients and for monitoring response to therapy in metastatic breast cancer patients.

Prescription Use __X__ **AND/OR** **Over-the-counter Use** _____
(Per 21 CFR 801 Subpart D) **(21 CFR 801 Subpart C)**

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of -In Vitro Diagnostic Devices (OIVD)

Leena Philip

Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510K k100344

Indications for Use Statement

510(k) Number (if known): k100344

Device Name:

Dimension Vista® LOCI 7 Calibrator

Indications for Use:

The LOCI 7 CAL is an *in vitro* diagnostic product for the calibration of Cancer Antigen 15-3 (CA 15-3) and Cancer Antigen 19-9 (CA 19-9) methods on the Dimension Vista® system.

Prescription Use __X__ **AND/OR** **Over-the-counter Use** _____
(Per 21 CFR 801 Subpart D) **(21 CFR 801 Subpart C)**

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of -In Vitro Diagnostic Devices (OIVD)

Reena Philip

Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510K k100344